Severe Influenza Cohort

Study Overview
=================
Brief Summary
-----------------
Influenza is a major cause of morbidity and mortality. The investigators first goal is to evaluate soluble HLA-G5 isoform serum level as a potential marker of greater risk of death from Influenza respiratory illness in adult and pediatric patients hospitalized in reanimation. Secondly, the investigators collected respiratory samples in order to study the transcriptomic profiles of influenza-infected patients with severe symptoms.

Official Title
-----------------
Identification, in Patients Admitted to Intensive Care for Severe Influenza Respiratory Infection, of a Predictive Biomarker of Respiratory Distress

Conditions
-----------------
Influenza, Severe Respiratory Infection

Intervention / Treatment
-----------------
* Other: influenza cohort


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient (Adult or Pediatric) Hospitalized in reanimation With a laboratory confirmed Influenza That agree to take part in the study Affiliated to National Health Insurance For ancillary group : Adult at least 60 years old Presenting at hospital for a blood test Exclusion Criteria: non willing to participate Influenza infection with no respiratory symptoms pregnancy For ancillary group : Presence of immunodepression defined by: Cancer, or cancer cured for less than 2 years Corticosteroids, Methotrexate (MTX), anti Tumor Necrosis Factor (TNF), anti-CD20 Infection in progress (fever)

Ages Eligible for Study
-----------------
Minimum Age: 1 Month
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: influenza cohort<br>Influenza is a major cause of morbidity and mortality. The investigators' first goal is to evaluate soluble HLA-G5 isoform serum level as a potential marker of greater risk of death from Influenza respiratory illness in adult and pediatric patients hospitalized in reanimation. 1 control group of 30 patients (ancillary study) will be constitued to have reference values of the HLA-G5 marker. Secondly, the investigators collected respiratory samples in order to study the transcriptomic profiles of influenza-infected patients with severe symptoms. | Other: influenza cohort<br>* Influenza is a major cause of morbidity and mortality. The investigators' first goal is to evaluate soluble HLA-G5 isoform serum level as a potential marker of greater risk of death from Influenza respiratory illness in adult and pediatric patients hospitalized in reanimation. Secondly, the investigators collected respiratory samples in order to study the transcriptomic profiles of influenza-infected patients with severe symptoms.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in ratio of the partial pressure of oxygen in arterial blood (PaO2) to the inspired oxygen fraction (FiO2), from admission at 7 days post-admission | decreased arterial PaO2/FiO2 ratio ≤ 100 mmHg (≤ 13.3 kPa) | The first, third, fifth and seventh day of hospitalization in reanimation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All cause mortality |  | 90 days after hospitalization | 
| Extracorporeal membrane oxygenation requirement |  | 90 days after hospitalization | 
| SOFA score (Adult) PELOD (Pediatric) | Elevated Score is considered as an evidence of clinical gravity | The first, third, fifth and seventh day of hospitalization in reanimation |